Novel doxorubicin / folate-targeted trans-ferulic acid-loaded PLGA nanoparticles combination: In-vivo superiority over standard chemotherapeutic regimen for breast cancer treatment.

Helmy, Sahar A; El-Mofty, Saif; El Gayar, Amal M; El-Sherbiny, Ibrahim M; El-Far, Yousra M

Helmy, Sahar A; El-Mofty, Saif; El Gayar, Amal M; El-Sherbiny, Ibrahim M; El-Far, Yousra M.

Affiliation

Helmy SA; Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
El-Mofty S; Nanomedicine Research Labs, Center for Materials Sciences, Zewail City of Science and Technology, 6th October City, 12578 Giza, Egypt.
El Gayar AM; Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
El-Sherbiny IM; Nanomedicine Research Labs, Center for Materials Sciences, Zewail City of Science and Technology, 6th October City, 12578 Giza, Egypt. Electronic address: ielsherbiny@zewailcity.edu.eg.
El-Far YM; Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. Electronic address: yousraelfar@mans.edu.eg.

Biomed Pharmacother ; 145: 112376, 2022 Jan.

Article de En | MEDLINE | ID: mdl-34749055

Sujet(s)
Mots clés

AC regimen; Breast cancer; Dox/FA-PLGA-TFA NPs combination; Notch-Wnt synergies; Permeability Glycoprotein; Safety profile

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du sein / Doxorubicine / Nanoparticules / Antibiotiques antinéoplasiques Type d'étude: Guideline Aspects: Patient_preference Limites: Animals Langue: En Journal: Biomed Pharmacother Année: 2022 Type de document: Article Pays d'affiliation: Égypte Pays de publication: France

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google